Pre-demographic dividend vs Zambia: Antiretroviral therapy coverage for PMTCT
Pre-demographic dividend
84.4%
in 2024
Zambia
98.0%
in 2024
Pre-demographic dividend rank
9th
Zambia rank
9th
Antiretroviral therapy coverage for PMTCT over time
- Pre-demographic dividend
- Zambia
How they compare
Zambia currently reports 98.0% against 84.4% in Pre-demographic dividend, a difference of 13.6%.
That makes Zambia's figure about 1.2 times Pre-demographic dividend's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Zambia ahead.
Pre-demographic dividend ranks 9th and Zambia ranks 9th of 15 groups.
Zambia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Pre-demographic dividend | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 18.1% | 27.6% | 9.5% | Zambia |
| 2010s | 69.9% | 80.8% | 10.9% | Zambia |
| 2020s | 84.0% | 94.6% | 10.6% | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Pre-demographic dividend or Zambia?
- Zambia, at 98.0% against 84.4% in Pre-demographic dividend as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Pre-demographic dividend and Zambia?
- 13.6%, with Zambia ahead.
- How many years of comparable data are there for Pre-demographic dividend and Zambia?
- 25 years are reported by both, from 2000 to 2024.
- How do Pre-demographic dividend and Zambia rank globally for antiretroviral therapy coverage for pmtct?
- Pre-demographic dividend ranks 9th and Zambia ranks 9th of 15 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).